High Performance Camera Offers Superior Resolution Imaging for Biotech Applications

Fremont, Calif. - June 7, 2004 —PerkinElmer Optoelectronics, a global technology leader providing market-driven integrated solutions for biomedical and industrial applications, today announced that its ColdBlue™ Cooled CCD Camera has received USB 2.0 certification from the National Technical Systems, Inc. (Nasdaq: NTSC), a leading provider of quality and conformance testing and managed services. PerkinElmer's ColdBlue is the first high resolution cooled camera to be independently USB 2.0 certified, ensuring the highest level of integration and performance.

PerkinElmer's ColdBlue Cooled CCD Cameras are ideal for OEM biotech manufacturers in proteomic applications including protein peptide, DNA, RNA and amino acid sequencing and expression, fluorescent microscopy, and luminescence.

With a high pixel resolution of 2184 x 1472, extremely low noise level (typically 8 electrons), small footprint and a 16-bit dynamic range, the ColdBlue allows users to detect the faintest signals with the highest clarity. By using off-the-shelf standard lenses and not requiring third-party cables or frame grabbers, ColdBlue lowers the cost of ownership. Its USB 2.0 certified interface allows for easy design-in, plug-and-play compatibility, and a quick set up that takes just hours not weeks, saving time and money.

"PerkinElmer has over 30 years experience supplying CCD solutions, and we have applied that expertise to our new ColdBlue Cooled CCD Cameras," said John Murphy, president, PerkinElmer Optoelectronics. "Independent USB 2.0 certification validates that PerkinElmer's ColdBlue will perform to specification, giving biotech manufacturers yet another reason to select PerkinElmer as their supplier of choice."

PerkinElmer's ColdBlue Cooled CCD Camera is available now direct from PerkinElmer.

Factors Affecting Future Performance

This press release contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share, cash flow and revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities. Words such as "believes," "intends," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management's current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation: (1) our failure to introduce new products in a timely manner; (2) our ability to execute acquisitions and license technologies, or to successfully integrate acquired businesses and licensed technologies into our existing business or to make them profitable; (3) fluctuations in the global economic and political environments; (4) markets into which we sell our products decline or do not grow as anticipated; (5) our failure to adequately protect our intellectual property; (6) the loss of any of our licenses or licensed rights; (7) our ability to compete effectively; (8) fluctuation in our quarterly operating results and our ability to adjust our operations to address unexpected changes; (9) significant disruption in third-party package delivery and import/export services or significant increases in prices for those services; (10) disruptions in the supply of raw materials and supplies; (11) our ability to produce an adequate quantity of products to meet our customers' demands; (12) the manufacture and sale of products may expose us to product liability claims; (13) our failure to maintain compliance with applicable government regulations; (14) regulatory changes; (15) our failure to comply with health care industry regulations; (16) economic, political and other risks associated with foreign operations; (17) our ability to retain key personnel; (18) restrictions in our credit agreements; (19) our ability to realize the full value of our intangible assets; (20) significant fluctuations in our stock price; and (21) other factors which we describe under the caption "Risk Factors" in our most recent annual report on Form 10-K and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

About PerkinElmer, Inc.

PerkinElmer, Inc. is a global leader focused on improving the health and safety of people and the environment. The Company reported revenue of approximately $2 billion in 2008, has around 8,500 employees serving customers in more than 150 countries, and is a component of the S&P 500 Index. Additional information is available through www.perkinelmer.com or 1-877-PKI-NYSE.

		For Further Information:
		Media Contact: Kristen Kmetetz Porter Novelli Life Sciences 617.897.8272 (office) Kristen.kmetetz@porternovelli.com or Francine S. Bernitz Marketing Director, Illumination and Detection Solutions PerkinElmer, Inc. Francine.bernitz@perkinelmer.com 978.224.4321 (office) 781.789.3178 (cell)